Cargando…

Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease

Introduction The clinical course of non-alcoholic fatty liver disease (NAFLD) in its long term may follow a benign course or have an adverse outcome leading to hepatocellular carcinoma (HCC) or end-stage liver disease requiring liver transplantation. Such patients represent only a small proportion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumari, Bandana, Sharma, Sadhana, Kumar, Ramesh, Dipankar, Satish, Naik, Bijaya N, Banerjee, Ayan, Kumar, Sushil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830306/
https://www.ncbi.nlm.nih.gov/pubmed/35165568
http://dx.doi.org/10.7759/cureus.21110
_version_ 1784648247448436736
author Kumari, Bandana
Sharma, Sadhana
Kumar, Ramesh
Dipankar, Satish
Naik, Bijaya N
Banerjee, Ayan
Kumar, Sushil
author_facet Kumari, Bandana
Sharma, Sadhana
Kumar, Ramesh
Dipankar, Satish
Naik, Bijaya N
Banerjee, Ayan
Kumar, Sushil
author_sort Kumari, Bandana
collection PubMed
description Introduction The clinical course of non-alcoholic fatty liver disease (NAFLD) in its long term may follow a benign course or have an adverse outcome leading to hepatocellular carcinoma (HCC) or end-stage liver disease requiring liver transplantation. Such patients represent only a small proportion of all NAFLD cases, making case finding a real challenge. Aims This study was planned to test the efficacy of simple laboratory parameters for their ability to screen advanced cases of NAFLD who need early attention to extricate them from the cumbersome outcome. Material and method The study protocol enrolled 129 diagnosed cases of NAFLD. Patients were categorized as group I with mild/moderate fibrosis (MF) comprising of F0 to F2 and group II with advanced fibrosis (AF) comprising of F3 and F4 based on Fibroscan kPa (kilopascal) score. Results Group I consisted of 96 MF patients, while group II included 33 AF patients. Mean values of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), triglyceride (TG), triglyceride/high-density lipoprotein (TG/HDL) ratio, total cholesterol/high-density lipoprotein (TC/HDL) ratio, and platelet distribution width (PDW) were significantly higher in patients with AF (group II), while platelet count (PC) was significantly lower in group II. The area under the receiver operative characteristic (AUROC) curve was highest for PDW [0.730 (0.644-0.815)] and TG/HDL ratio [0.719 (0.612-0.827)]. TG/HDL ratio at a cut-off of >2.4 had a sensitivity and specificity of 84.85% and 34.38%, respectively, and PDW at a cut-off of >16.40 had a sensitivity and specificity of 84.85% and 54.17%, respectively. Conclusion Decent sensitivity at particular cut-offs for TG/HDL ratio and PDW makes them suitable to be applied for screening advanced cases of NAFLD that require early ministration and medication to block its further progression to its intricate form.
format Online
Article
Text
id pubmed-8830306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-88303062022-02-13 Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease Kumari, Bandana Sharma, Sadhana Kumar, Ramesh Dipankar, Satish Naik, Bijaya N Banerjee, Ayan Kumar, Sushil Cureus Genetics Introduction The clinical course of non-alcoholic fatty liver disease (NAFLD) in its long term may follow a benign course or have an adverse outcome leading to hepatocellular carcinoma (HCC) or end-stage liver disease requiring liver transplantation. Such patients represent only a small proportion of all NAFLD cases, making case finding a real challenge. Aims This study was planned to test the efficacy of simple laboratory parameters for their ability to screen advanced cases of NAFLD who need early attention to extricate them from the cumbersome outcome. Material and method The study protocol enrolled 129 diagnosed cases of NAFLD. Patients were categorized as group I with mild/moderate fibrosis (MF) comprising of F0 to F2 and group II with advanced fibrosis (AF) comprising of F3 and F4 based on Fibroscan kPa (kilopascal) score. Results Group I consisted of 96 MF patients, while group II included 33 AF patients. Mean values of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), triglyceride (TG), triglyceride/high-density lipoprotein (TG/HDL) ratio, total cholesterol/high-density lipoprotein (TC/HDL) ratio, and platelet distribution width (PDW) were significantly higher in patients with AF (group II), while platelet count (PC) was significantly lower in group II. The area under the receiver operative characteristic (AUROC) curve was highest for PDW [0.730 (0.644-0.815)] and TG/HDL ratio [0.719 (0.612-0.827)]. TG/HDL ratio at a cut-off of >2.4 had a sensitivity and specificity of 84.85% and 34.38%, respectively, and PDW at a cut-off of >16.40 had a sensitivity and specificity of 84.85% and 54.17%, respectively. Conclusion Decent sensitivity at particular cut-offs for TG/HDL ratio and PDW makes them suitable to be applied for screening advanced cases of NAFLD that require early ministration and medication to block its further progression to its intricate form. Cureus 2022-01-11 /pmc/articles/PMC8830306/ /pubmed/35165568 http://dx.doi.org/10.7759/cureus.21110 Text en Copyright © 2022, Kumari et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Genetics
Kumari, Bandana
Sharma, Sadhana
Kumar, Ramesh
Dipankar, Satish
Naik, Bijaya N
Banerjee, Ayan
Kumar, Sushil
Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title_full Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title_fullStr Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title_full_unstemmed Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title_short Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
title_sort efficacy of lipid ratios and platelet distribution width for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830306/
https://www.ncbi.nlm.nih.gov/pubmed/35165568
http://dx.doi.org/10.7759/cureus.21110
work_keys_str_mv AT kumaribandana efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT sharmasadhana efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT kumarramesh efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT dipankarsatish efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT naikbijayan efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT banerjeeayan efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease
AT kumarsushil efficacyoflipidratiosandplateletdistributionwidthforassessmentofliverfibrosisinpatientswithnonalcoholicfattyliverdisease